bioAffinity Technologies
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 75
- Market Cap
- $21.7M
- Introduction
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
bioAffinity Technologies Secures $3.25 Million in Funding to Advance Early Cancer Detection Technology
bioAffinity Technologies has successfully closed a $3.25 million offering, issuing over 10 million shares of common stock along with warrants to purchase additional shares at $0.32 per unit.
© Copyright 2025. All Rights Reserved by MedPath